Related Experiment Video
Updated: Jun 20, 2026
CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis
Published on: April 25, 2022
CCR8 as a Therapeutic Novel Target: Omics-Integrated Comprehensive Analysis for Systematically Prioritizing
Nari Kim1, Mi-Hyun Kim2, Junhee Pyo3
1Department of Medical Science, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
Abstract:
Target identification is a crucial process in drug development, aiming to identify key proteins, genes, and signal pathways involved in disease progression and their relevance in potential therapeutic interventions. While C-C chemokine receptor 8 (CCR8) has been investigated as a candidate anti-cancer target, comprehensive multi-omics analyzes across various indications are limited. In this study, we conducted an extensive bioinformatics analysis integrating genomics, proteomics, and transcriptomics data to establish CCR8 as a promising anti-cancer drug target. Our approach encompassed data collection from diverse knowledge resources, gene function analysis, differential gene expression profiling, immune cell infiltration assessment, and strategic prioritization of target indications. Our findings revealed strong correlations between CCR8 and specific cancers, notably Breast Invasive Carcinoma (BRCA), Colon Adenocarcinoma (COAD), Head and Neck Squamous Cell Carcinoma (HNSC), Rectum adenocarcinoma (READ), Stomach adenocarcinoma (STAD), and Thyroid carcinoma (THCA). This research advances our understanding of CCR8 as a potential target for anti-cancer drug development, bridging the gap between molecular insights and creating opportunities for personalized treatment of solid tumors.
Insights
This study establishes C-C chemokine receptor 8 (CCR8) as a promising anti-cancer drug target. Bioinformatics analysis revealed CCR8
Area of Science:
- Oncology
- Bioinformatics
- Drug Discovery
Background:
- Target identification is critical in drug development for pinpointing disease-related genes and pathways.
- C-C chemokine receptor 8 (CCR8) has shown potential as an anti-cancer target, but multi-omics data across indications remain limited.
Purpose of the Study:
- To conduct a comprehensive bioinformatics analysis integrating multi-omics data to validate CCR8 as a viable anti-cancer drug target.
- To identify specific cancer types where CCR8 shows significant correlation for potential therapeutic intervention.
Main Methods:
- Integrated genomics, proteomics, and transcriptomics data from diverse knowledge resources.
- Performed gene function analysis, differential gene expression profiling, and immune cell infiltration assessment.
- Prioritized target indications based on integrated data analysis.
Main Results:
- Established strong correlations between CCR8 expression and several cancers, including Breast Invasive Carcinoma (BRCA), Colon Adenocarcinoma (COAD), Head and Neck Squamous Cell Carcinoma (HNSC), Rectum adenocarcinoma (READ), Stomach adenocarcinoma (STAD), and Thyroid carcinoma (THCA).
- Demonstrated the potential of CCR8 as a target for anti-cancer drug development across multiple solid tumor types.
Conclusions:
- CCR8 is a promising target for developing novel anti-cancer therapeutics.
- This research bridges molecular insights with therapeutic opportunities for personalized treatment of solid tumors.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:29Pharmacogenomics: Identification of New Drug Targets